A potential new treatment for Alzheimer’s disease … and other research

Deep biology approach to Alzheimer’s diseaseAfter all the debate over the past couple of years about lecanemab, we now have another type of Alzheimer’s disease treatment to discuss. According to the authors of a phase 2 trial in Nature Medicine, p75 neurotrophin receptor (p75NTR) modulation offers a “deep biology” approach by targeting “receptors and/or signalling networks that control manifold fundamental cellular pathways.” In the trial 242 participants with mild to moderate Alzheimer’s disease were allocated to either treatment (with a p75NTR treatment called LM11A-31) or placebo. The safety and tolerability endpoints were met, and, although there was no significant difference in cognitive function between the treatment and placebo groups, differences were seen in brain biomarkers on magnetic resonance imaging and positron emission tomography in the treatment arms. Phase 3 studies will tell us more about whether these differences are clinically relevant.Nat Med doi:10.1038/s41591-024-02977-wAdding biomarkers to CVD risk tools—not worth the…
Read Original Article: A potential new treatment for Alzheimer’s disease … and other research »